Lenalidomide 15mg Capsule

Lenalidomide 15mg Capsule is an oral immunomodulatory anticancer medicine used in approved hematologic-oncology treatment settings. Generic lenalidomide contains the same active ingredient as Revlimid® 15mg, with manufacturer, excipients and packaging varying by product. Market terminology also includes lénalidomide 15 mg, Lenalidomid 15 mg, 레날리도마이드 15mg and леналидомид 15 мг. Current U.S. labeling lists 15mg as an available capsule strength.

Product Information

Generic Name

Lenalidomide

Strength

15mg

Dosage Form

Hard Capsule

Route

Oral

Drug Class

Immunomodulatory Antineoplastic Agent

Reference Brand

Revlimid® 15mg

Active Ingredient

Lenalidomide

Prescription Status

Prescription medicine

Pack Size

Varies; 7, 14, 21 and 28-capsule presentations are documented across markets

Manufacturer

Varies by generic product

Generic Revlimid® 15mg

Lenalidomide 15mg Capsules are generic medicines related to Revlimid® 15mg. French public medicine records explicitly place Lenalidomide Accord 15mg in the generic group equivalent to Revlimid 15mg, and EU information confirms that generic lenalidomide products contain the same active substance as the reference medicine.

Commercial Availability

Search intent around this product includes lenalidomide 15mg price, lenalidomide 15mg capsules, generic Revlimid 15mg, lenalidomide 15mg pharmacy, Revlimid 15mg 21 capsules and lenalidomide 15mg online. Exact availability, manufacturer, pack size and prescription process depend on the destination market.

Depending on the country-specific approval, lenalidomide is used in treatment regimens for multiple myeloma, certain myelodysplastic syndromes with deletion 5q, and selected lymphoma indications. U.S. labeling currently specifies multiple myeloma and transfusion-dependent low- or intermediate-1-risk MDS associated with deletion 5q, while European labeling includes additional lymphoma uses.

Lenalidomide is a high-risk prescription oncology medicine. Major labeled risks include embryo-fetal toxicity, blood-count abnormalities and venous/arterial thromboembolism. U.S. labeling requires restricted distribution through the Lenalidomide REMS program; pregnancy must be excluded before treatment in females of reproductive potential.

Treatment should be prescribed and monitored by an appropriately qualified oncology clinician. Capsules should be swallowed whole and not opened, broken or chewed.